Program
encequidar
Also written as “HM30181AK tablet + Irinotecan tablets”, “Oral Paclitaxel in combination with Encequidar tablet” and “Encequidar tablet”.
Its studies are mostly in Breast Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hanmi Pharmaceutical | 40 open or running | phase 1since Aug 6, 2009 | Aug 6, 2009 | none ahead |
| Health Hope Pharma | 22 open or running | phase 3since Feb 14, 2025 | Feb 14, 2025 | Dec 2026phase 1 · NCT07580833 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 6, 2009First study: phase 1 study in HealthyNew to Hanmi PharmaceuticalHanmi Pharmaceutical · NCT00954304 · 30 enrolled · Korea, Republic of
- Sep 16, 20092 phase 1 studies in Advanced Solid MalignanciesHanmi Pharmaceutical · NCT00979563, NCT00986843
- Dec 5, 2011Phase 1 study in Advanced Solid TumorsHanmi Pharmaceutical · NCT01491204 · 25 enrolled
- Feb 14, 2025Health Hope Pharma's first study: phase 3 study in Breast NeoplasmsNew to Health Hope PharmaHealth Hope Pharma · NCT06835400 · 340 planned
- Mar 24, 2026Phase 1 study in Breast NeoplasmsHealth Hope Pharma · NCT07580833 · 46 planned
Ahead
- Dec 2026Primary completion: phase 1 study in Breast NeoplasmsHealth Hope Pharma · NCT07580833
- Apr 2028Primary completion: phase 3 study in Breast NeoplasmsHealth Hope Pharma · NCT06835400
TargetBeta
“P-glycoprotein 1 inhibitor”ChEMBL 37, by rule
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07580833Breast Neoplasms | 1 | Not yet recruiting | Health Hope Pharma | Dec 2026 | 46 |
| NCT06835400Breast Neoplasms | 3 | Not yet recruiting | Health Hope Pharma | Apr 2028 | 340 |
| NCT01491204Advanced Solid Tumors | 1 | Completed | Hanmi Pharmaceutical | Oct 2008 | 25 |
| NCT00986843Advanced Solid Malignancies · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Feb 2010 | 14 |
| NCT00979563Advanced Solid Malignancies · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Mar 2010 | 15 |
| NCT00954304Healthy · Korea, Republic of | 1 | Completed | Hanmi Pharmaceutical | Aug 2009 | 30 |
How it is read
Names in the registry
- “HM30181AK tablet + Irinotecan tablets”, 2 entries
- “Oral Paclitaxel in combination with Encequidar tablet”, 1 entry
- “Encequidar tablet”, 1 entry
- “Paclitaxel+HM30181”, 1 entry
- “HM30181AK 1mg”, 1 entry
Conditions, from the studies’ own filings
- Breast Neoplasms, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.